Immuno Aktiengesellschaft Fur Chemisch-medizinische Produkte

Fritz Elsinger

Johann J Eibl

Otto Schwarz

Yendra Linnau

Anton Philapitsch

Friedrich Dorner

Gunter Wober

Karl Trambauer

Wolfgang Frechinger

There is disclosed a method of inactivating reproducible filterable pathogens in blood plasma products by applying elevated temperatures. The blood plasma products are heat treated in a solid state in a closed inactivation container in the presence of specific amounts of water and organic compounds, provided that the water substantially remains physically bound to the blood plasma products, while the organic compound is present in a gaseous form in the atmosphere. The water content of the blood plasma products is 0.08 to 0.40. The concentration of the organic compounds in the gaseous phase is 0.01 to 10 g per liter of container volume.

Method of inactivating reproducible filterable pathogens in blood plasma

A method of inactivating viruses in blood products is described, wherein the blood products are heat-treated in a humid or in a solid state in the presence of inorganic or organic hydroxyl group-containing compounds having an H.sup.+ -dissociation constant of &lt;10.sup.-11 in a concentration of more than 0.05 (5% by weight) and less than 0.70 (70% by weight). The hydroxyl group-containing compounds may be water, methanol, ethanol or mannitol. The temperature may amount up to 121.degree. C., the heat treatment may last from 1 s to 100 h. The inactivation method may be applied for producing blood products selected from enzymes, proenzymes including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma, the inactivation destroying any reproducible filterable pathogens that might be present.

Method of inactivating reproducible filterable pathogens in blood

In a method of producing a blood-coagulation-promoting preparation based on human proteins and having a content of coagulation factors II, VII, IX and X and factor-VIII-inhibitor-bypassing-activity (FEIBA), human plasma is treated with sulphated high-polymer carbohydrates and/or with basic ion exchangers, the protein mixture with generated FEIB-activity is adsorbed on the ion exchanger, and the preparation is gained by elution and concentration.

Blood-coagulation-promoting preparation based on human proteins and a

In a method of producing plasma fractions free of side-effects by purification and step-wise enrichment of plasma proteins in the presence of calcium-binding anticoagulants, also fast reactive (avid) antithrombin is present, wherein a concentration of the fast reacting (avid) antithrombin of 0.05 to 50 units per ml of the respective solution is maintained during all fractionation process steps.

Method of producing plasma fractions free of side-effects using

In a method of producing a blood-coagulation-promoting preparation from human blood plasma, which preparation contains a new blood-coagulating substance called 'FEIBA', human plasma with citrate ions is treated with water-insoluble inorganic coagulation-physiologically-surface-active substances in the absence of free calcium ions, thus generating 'FEIBA', the water-insoluble substances are separated, the supernatant is treated with basic ion exchangers, wherein 'FEIBA' and the coagulation factors II-VII-IX-X adhere to the ion exchangers, and 'FEIBA' and the factors II-VII-IX-X are eluted and concentrated.

Growing community of inventors

Vienna, Austria

Fritz Elsinger